Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
| dc.contributor.author | Zauderer, MG | en_US |
| dc.contributor.author | Szlosarek, PW | en_US |
| dc.contributor.author | Le Moulec, S | en_US |
| dc.contributor.author | Popat, S | en_US |
| dc.contributor.author | Taylor, P | en_US |
| dc.contributor.author | Planchard, D | en_US |
| dc.contributor.author | Scherpereel, A | en_US |
| dc.contributor.author | Jahan, TM | en_US |
| dc.contributor.author | Koczywas, M | en_US |
| dc.contributor.author | Forster, M | en_US |
| dc.contributor.author | Cameron, RB | en_US |
| dc.contributor.author | Peikert, T | en_US |
| dc.contributor.author | Argon, EK | en_US |
| dc.contributor.author | Michaud, N | en_US |
| dc.contributor.author | Yang, J | en_US |
| dc.contributor.author | Kansra, V | en_US |
| dc.contributor.author | Fennell, DA | en_US |
| dc.date.accessioned | 2020-11-25T14:25:32Z | |
| dc.date.available | 2020-11-25T14:25:32Z | |
| dc.date.issued | 2020-05-20 | en_US |
| dc.identifier.issn | 0732-183X | en_US |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/68686 | |
| dc.format.extent | 9058 - 9058 | en_US |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.title | Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma. | en_US |
| dc.type | Article | |
| dc.identifier.doi | 10.1200/jco.2020.38.15_suppl.9058 | en_US |
| pubs.issue | 15_suppl | en_US |
| pubs.notes | Not known | en_US |
| pubs.volume | 38 | en_US |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
